Harvard Bioscience Inc (NASDAQ: HBIO)

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications including research, drug and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. The company operates globally with products and services sold to academic institutions, government laboratories, pharmaceutical and biotechnology companies, and contract research organizations. Its operations span the United States, Europe and China through a combination of direct and distribution channels.

Harvard Bioscience generates revenue through the sale of its proprietary products, consumables, software and services, as well as the distribution of third-party products. Its core offerings include instruments and systems for molecular and cellular analysis, electrophysiology, and preclinical testing. The company’s products serve researchers and developers across the life sciences workflow from early discovery to preclinical validation.

The company operates through the following segments: Cellular and Molecular (CMT) and Preclinical.

• Cellular and Molecular (CMT): This segment focuses on products supporting research in molecular, cellular, organ and organoid technologies, with applications in bioproduction and in vitro testing of cell lines and organoids. Key brands under this segment include Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner. The CMT product family includes electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, high precision syringe and peristaltic pumps, and scientific measuring instrumentation such as data acquisition systems and micro-electrode array solutions. Notable innovations include the BTX electroporation system for bioproduction and the MeshMEA™ system for organoid research in cardiac and neurological applications.

• Preclinical: This segment provides products for preclinical research and testing, supporting data collection and analysis for safety and regulatory compliance in drug development. Key brands include DSI, Panlab, Hugo Sachs and Buxco. The segment offers implantable and externally worn telemetry systems such as the SoHo™ Small Animal Implantable Telemetry System, behavioral and surgical instruments, turn-key respiratory solutions, inhalation and exposure systems, GLP-capable data acquisition and analysis systems, and the VivaMars™ behavioral monitoring system launched in 2023 for high-throughput testing by CROs, pharmaceutical and biotechnology companies, and government laboratories.

Harvard Bioscience holds a competitive position in the life science tools market, competing with major players such as Agilent, Becton Dickinson, Bio-Rad, Danaher, Eppendorf, Thermo Fisher Scientific, Revvity and Waters Corporation. The company differentiates itself through product performance, including quality, reliability, speed, technical support, price and delivery time, leveraging its long history and specialized expertise in niche areas like electrophysiology and telemetry.

The company serves a global customer base comprising pharmaceutical and biotechnology companies such as Abbott, Amgen, AstraZeneca, Bayer, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer and Regeneron. Academic customers include institutions like Baylor College of Medicine, Cambridge University, Harvard University, Imperial College London, Johns Hopkins University, Stanford, the University of California system, University of Pennsylvania, University of Pittsburgh, University of Texas and Yale University. Contract research organization clients include Charles River Laboratories, Labcorp and Wuxi AppTec, with no single customer accounting for more than 10% of revenue in recent years.